Could simvastatin be a treatment for secondary progressive MS?
In this video, Professor Jeremy Chataway talks about the MS STAT-2 trial and how it could help people with MS.
- Lead researcher:
- Professor Jeremy Chataway
- Based at:
- UCL Institute of Neurology
- MS Society funding:
- £1.17 million
We’re proud to co-fund this phase 3 trial testing if simvastatin can slow progression in secondary progressive MS. If successful, simvastatin could be one of the first treatments licensed for this type of MS.
The MS-STAT2 trial will test if simvastatin can slow disability progression over a three-year period. They will measure progression using the Expanded Disability Status Scale, which assesses changes in walking and other MS symptoms.
The trial began in summer 2017 and will involve 1,180 people with secondary progressive MS. It will take six years to complete and involve over 30 trial centres across the UK.
Recruitment for MS-STAT2 is now open across the UK until the end of 2019. If you'd like to be considered to take part in the trial, you can register your interest on the UCL website.
How will it help people with MS?
Right now there are no treatments that can slow or stop the accumulation of disability associated with MS. If this trial is successful, simvastatin could be one of the first treatments licensed for secondary progressive MS.
The difference you can make
The race is on to find therapies that will slow progression. You can help speed up the process by supporting projects like this.